1. Scrip
  2. >>Business

Potential For Functional Cure Opens Up With GSK’s Hepatitis B Candidate

Durability Test Remains

 
• By Andrew McConaghie

Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.

#EASL
Hepatitis B was a big focus at this year's International Liver Congress, hosted by European Association for the Study of the Liver (EASL) in London • Source: Steve Forrest & Andrew McConnell / EASL

GSK has unveiled promising interim Phase IIb results of hepatitis B candidate, bepirovirsen, which could put it on the path to providing a functional cure for more chronic patients.

The antisense oligonucleotide therapy rendered the virus undetectable in the blood of nearly 30% of patients on the B-Clear study...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 
• By Jessica Merrill

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By Joseph Haas

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

2025’s Biggest Launches – Half-Year Progress Report

 
• By Andrew McConaghie

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.